Can Zn Be a Critical Element in COVID-19 Treatment?
Abstract The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
---|---|
Enthalten in: |
Biological trace element research - 199(2020), 2 vom: 26. Mai, Seite 550-558 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rahman, Mohammad Tariqur [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Anti-viral drugs |
---|
doi: |
10.1007/s12011-020-02194-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR042436265 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR042436265 | ||
003 | DE-627 | ||
005 | 20230519081512.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201218s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12011-020-02194-9 |2 doi | |
035 | |a (DE-627)SPR042436265 | ||
035 | |a (DE-599)SPRs12011-020-02194-9-e | ||
035 | |a (SPR)s12011-020-02194-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 570 |q ASE |
100 | 1 | |a Rahman, Mohammad Tariqur |e verfasserin |4 aut | |
245 | 1 | 0 | |a Can Zn Be a Critical Element in COVID-19 Treatment? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19. | ||
650 | 4 | |a Anti-viral drugs |7 (dpeaa)DE-He213 | |
650 | 4 | |a Chloroquine |7 (dpeaa)DE-He213 | |
650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
650 | 4 | |a RNA dependent RNA polymerase |7 (dpeaa)DE-He213 | |
650 | 4 | |a Zinc transporter |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pneumocytes |7 (dpeaa)DE-He213 | |
700 | 1 | |a Idid, Syed Zahir |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biological trace element research |d [S.l.] : Springer US, 1979 |g 199(2020), 2 vom: 26. Mai, Seite 550-558 |w (DE-627)SPR023603453 |w (DE-600)2072581-4 |x 1559-0720 |7 nnns |
773 | 1 | 8 | |g volume:199 |g year:2020 |g number:2 |g day:26 |g month:05 |g pages:550-558 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12011-020-02194-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 199 |j 2020 |e 2 |b 26 |c 05 |h 550-558 |